Xaira Therapeutics is an integrated biotechnology company utilizing AI that aims to transform the treatment of disease. The company has a mission to rethink the drug discovery and development process by honing in on machine learning research, expansive data generation, and robust therapeutic product development. Xaira Therapeutics was founded by Arvind Rajpal, David Baker, Don Kirkpatrick, Hetu Kamisetty, Joe Watchwell Watson, and Marc Tessier-Lavigne in 2024 and is headquartered in San Francisco, CA.
Xaira Therapeutics is an integrated biotechnology company utilizing AI that aims to transform the treatment of disease. The company has a mission to rethink the drug discovery and development process by honing in on machine learning research, expansive data generation, and robust therapeutic product development. Xaira Therapeutics was founded by Arvind Rajpal, David Baker, Don Kirkpatrick, Hetu Kamisetty, Joe Watchwell Watson, and Marc Tessier-Lavigne in 2024 and is headquartered in San Francisco, CA.
Xaira Therapeutics is a privately held company and is not publicly traded, therefore investing in Xaira Therapeutics pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
Can you sell shares of Xaira Therapeutics before it goes public?
You can seek to sell your shares in Xaira Therapeutics while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.
What is the pre-IPO value of my Xaira Therapeutics shares?
To determine the value of your Xaira Therapeutics shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your Xaira Therapeutics shares. You can also learn more about how to sell your private shares before getting started.
Is Xaira Therapeutics a publicly traded company?
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
To learn more about Xaira Therapeutics potential IPO
Will Xaira Therapeutics go IPO?
Xaira Therapeutics has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.
What is Xaira Therapeutics’ IPO price?
The Xaira Therapeutics IPO price does not exist at this time, as Xaira Therapeutics is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Xaira Therapeutics register for Forge Markets, today.
When was Xaira Therapeutics founded?
Xaira Therapeutics was founded in 2024.
What is Xaira Therapeutics funding to date?
Xaira Therapeutics has raised $1B to date.
Who are Xaira Therapeutics’s major investors?
Sv Angel
Menlo Ventures
Arch Venture Partners
Two Sigma Ventures
Lux Capital
Rsquared
Sequoia Capital
Wrf Capital
F-Prime
Parker Institute For Cancer Immunotherapy
Nea
Lightspeed Venture Partners
Byers Capital
Foresite Capital
New Enterprise Associates
R-Squared Ventures
Xaira Therapeutics Major Investors
Sv Angel
Menlo Ventures
Arch Venture Partners
Two Sigma Ventures
Lux Capital
Rsquared
Sequoia Capital
Wrf Capital
F-Prime
Parker Institute For Cancer Immunotherapy
Nea
Lightspeed Venture Partners
Byers Capital
Foresite Capital
New Enterprise Associates
R-Squared Ventures
Show All InvestorsShow Fewer Investors
Xaira Therapeutics Funding Rounds and Valuation
Funding History Chart
Funding Round Details
Funding Date
Share Class
Amount Raised
Price per Share
Post-Money Valuation
Key Investors
04/23/2024
Series Seed
$501.34MM
$xx.xx
$911.54MM
Arch Venture Partners, Byers Capital, Foresite Capital, F-Prime, Lightspeed Venture Partners, Lux Capital, Menlo Ventures, Nea, Parker Institute For Cancer Immunotherapy, Rsquared, Sequoia Capital, Sv Angel, Two Sigma Ventures
Price per Share
$xx.xx
Shares Outstanding
501,344,898
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Byers Capital, Foresite Capital, F-Prime, Lightspeed Venture Partners, Lux Capital, Menlo Ventures, Nea, Parker Institute For Cancer Immunotherapy, Rsquared, Sequoia Capital, Sv Angel, Two Sigma Ventures
04/23/2024
Series A
$500MM
$xx.xx
$2.65B
Arch Venture Partners, Byers Capital, Foresite Capital, F-Prime, Lightspeed Venture Partners, Lux Capital, Menlo Ventures, Nea, Parker Institute For Cancer Immunotherapy, Rsquared, Sequoia Capital, Sv Angel, Two Sigma Ventures
Price per Share
$xx.xx
Shares Outstanding
200,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Byers Capital, Foresite Capital, F-Prime, Lightspeed Venture Partners, Lux Capital, Menlo Ventures, Nea, Parker Institute For Cancer Immunotherapy, Rsquared, Sequoia Capital, Sv Angel, Two Sigma Ventures
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.
Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.
Updated on: Dec 17, 2024
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.
Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.
